Abstract
Developments in the receptor concept have greatly influenced our current knowledge of the beta-adrenoceptor. The triad of pharmacology, organic chemistry and studies in structure-activity relationships is discussed along historical lines, as it has been and still is an impetus for progress in the biochemistry of ligand-receptor interactions. With respect to the beta-adrenoceptor complex these advances which have led to a model in which three protein structures are functionally interacting within the frame of the cell wall: the beta-adrenoceptor, the regulatory guanine nucleotide binding protein, and the enzyme adenylate cyclase, are reviewed.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Dale HH. On some physiological actions of ergot. J Physiol (Lond) 1906;34:163–206.
Langley JN. On the reaction of cells and nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol (Lond) 1905;33:374–413.
Langley JN. On the physiology of the salivary secretion. J Physiol (Lond) 1878;1:339–69.
Fisher E. Einfluss der Configuration auf die Wirkung der Enzyme. Ber Dtsch Chem Ges 1894;27:2985–93.
Guldberg CM, Waage P. Études sur les affinité's chimiques. Cited in: Guggenheim EA. More about the laws of reaction rates and of equilibrium. J Chem Educ 1956;33:545–6.
Henri V. Théorie générale de l'action de quelques diastases. CR Acad Sci (D) (Paris) 1902;135:916–32.
Michaelis L, Menten ML. Die Kinetik der Invertwirkung. Biochem Z 1913;49:333–70.
Briggs GE, Haldane JBS. A note on the kinetics of enzyme action. Biochem J 1925;19:338–9.
Langmuir I. The adsorption of gases on plane surfaces of glass, mica and platinum. J Am Chem Soc 1918;40:1361–403.
Clark AJ. The reaction between acetylcholine and muscle cells. J Physiol (Lond) 1926;61:530–46.
Clark AJ. The mode of action of drugs on cells. London: Arnold Publishers, 1933.
Clark AJ. General Pharmacology. Heffter's Handbuch der experimentelle Pharmakologie. Vol. 4. Berlin: Springer-Verlag, 1937. (Reprinted in 1970 and 1973).
Gaddum JH. The action of adrenalin and ergotamine on the uterus of the rabbit. J Physiol (Lond) 1926;61:141–50.
Ravéntos J. Pharmacological actions of quaternary ammonium salts. Q J Exp Physiol 1937;26:361–74.
Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153:586–600.
Woodbury RA, Abreu BE. Influence of epinephrine upon the human gravid uterus. Am J Obstet Gynecol 1944;48:706–8.
Ariëns EJ, De Groot WM. Affinity and intrinsic activity in the theory of competitive inhibition, III. Homologous decamethonium derivatives and succinylcholine-esters. Arch Int Pharmacodyn Ther 1954;99:193–205.
Ariëns EJ, Simonis AM, De Groot WM. Affinity and intrinsic activity in the theory of competitive and non-competitive inhibition and an analysis of some forms of dualism in action. Arch Int Pharmacodyn Ther 1955;100:298–322.
Van Rossum JM. Cumulative dose-response curves. II. Technique for the making of dose-response curves on isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 1963;143:299–330.
Ariëns EJ. Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 1954;99:32–49.
Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956;11:379–93.
Ariëns EJ. Receptor theory and structure-activity relationships. In: Harper NJ, Simmonds AB, eds. Advances in Drug Research. Vol. 3. London: Academic Press, 1966:235–85.
Furchgott RF. The pharmacology of vascular smooth muscle. Pharmacol Rev 1955;7:183–265.
Nickerson M. Receptor occupancy and tissue response. Nature (Lond) 1956;178:697–8.
Sastry BVR, Cheng HC. Dissociation constants ofd- andl-lactoylcholines and related compounds at cholinergic receptors. J Pharmacol Exp Ther 1972;180:326–39.
Furchgott RF, Bursztyn P. Comparison of dissociation constants and of relative efficacies of selected agonists acting on parasympathetic receptors. Ann NY Acad Sci 1967;144:882–99.
Krall JF, Barrett JD, Korenman SG. Coupling of beta-adrenoceptors in rat uterine smooth muscle. Biol Reprod 1981;24:859–66.
Furchgott RF. The use of beta-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Harper NJ, Simmonds AB, eds. Advances in Drug Research. Vol. 3. London: Academic Press 1966:21–55.
Ariens EJ, Van Rossum JM, Koopman PC. Receptorreserve and threshold phenomena. I. Theory and experiments with autonomic drugs tested on isolated organs. Arch Int Pharmacodyn Ther 1960;127:459–78.
Van Rossum JM, Ariëns EJ. Receptor-reserve ana threshold phenomena. II. Theories on drug action and a quantitative approach to spare receptors and threshold values. Arch Int Pharmacodyn Ther 1962;136:385–413.
Ruffolo RR Jr, Rosing EL, Waddell JE. Receptor interactions of imidazolines. I. Affinity and efficacy for alpha-adrenergic receptors in rat aorta. J Pharmacol Exp Ther 1979;209:429–36.
Powell CE, Slater IH. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther 1958;122:480–8.
Moran NC, Perkins ME. Adrenergic block of the mammalian heart by a dichloro analogue of isoproterenol. J Pharmacol Exp Ther 1958;124:223–37.
Moran NC, Perkins ME. An evaluation of adrenergic blockade of the mammalian heart. J Pharmacol Exp Ther 1961;133:192–201.
Black JW, Stephenson JS. Pharmacology of a new adrenergic beta-receptor-blocking compound (nethalide). Lancet 1962;2:311–4.
Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic beta-receptor antagonist. Lancet 1964;1:1080–1.
Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature (Lond) 1967;214:597–8.
Lands AM, Groblewski GE, Brown TG Jr. Comparison of the action of isoproterenol and several related compounds on blood pressure, heart and bronchioles. Arch Int Pharmacodyn Ther 1965;161:68–75.
Arnold A, McAuliff JP, Luduena FP, Brown TG Jr. Lands AM. Lipolysis and sympathomimetic amines [Abstract]. Fed Proc 1966;25:500.
Dunlop D, Shanks RG. Selective blockade of adrenoceptive beta-receptors in the heart. Br J Pharmacol 1968;32:201–18.
Brittain RT, Farmer JB, Jack D, Martin LE, Simpson WT. New class of selective stimulants of beta-adrenergic receptors. Nature (Lond) 1968;219:861–2.
Carlsson E, Åblad B, Brandstrøm A, Carlsson B. Differentiated blockade of the chronotropic effects of various adrenergic stimuli in the cat heart. Life Sci 1972;11:953–8.
Harms HH, Zaagsma J, Van der Wal B. Betaadrenoceptor studies. III. On the beta-adrenoceptors in rat adipose tissue. Eur J Pharmacol 1974;25:87–91.
De Yente J, Bast A, Van Bree L, Zaagsma J. Beta-adrenoceptor studies, VI. Further investigations on the hybrid nature of the rat adipocyte betaadrenoceptor. Eur J Pharmacol 1980;63:73–83.
Arch JRS, Ainsworth AT, Cawthorne MA, et al. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature (Lond) 1982;309:163–5.
Wilson C, Wilson S, Piercy V, Sennitt MV, Arch JRS. The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists. Eur J Pharmacol 1984;100:309–19.
Koshland DE Jr. Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci USA 1958;44:98–104.
Belleau B. A molecular theory of drug action based on induced conformational perturbations of receptors. J Med Chem 1964;7:776–84.
Paton WDM. A theory of drug action based on the rate of drug-receptor combination. Proc R Soc Lond [Biol] 1961;154:21–69.
Furchgott RF. Receptor mechanisms. Ann Rev Pharmacol 1964;4:21–50.
Thron CD, Wand DR. The rate of action of atropine. J Pharmacol Exp Ther 1968;160:91–105.
Paton WDM, Rang HP. A kinetic approach to the mechanisms of drug action. In: Harper NJ, Simmonds AB, eds. Advances in Drug Research. Vol. 3. London: Academic Press 1966:57–80.
Rall TW, Sutherland EW. Formation of a cyclic adenosine ribonucleotide by tissue particles. J Biol Chem 1958;232:1065–76.
Sutherland EW, Robison GA. Role of cyclic-3′,5′AMP in responses to catecholamines and other hormones. Pharmacol Rev 1966;18:145–61.
Sutherland EW, Øye I, Butcher RW. The action of epinephrine and the role of the adenyl cyclase system in hormone action. Recent Prog Horm Res 1965;21:623–42.
Belleau B. Relationships between agonists, antagonists and receptor sites. In: Vane JR, Wolstenholme GEW, O'Connor M, eds. Ciba Foundation Symposium on Adrenergic Mechanisms. London, 1960. London: Churchill Livingstone, 1960:223–45.
Belleau B. Steric effects in catecholamine interactions with enzymes and receptors. Pharmacol Rev 1966;18: 131–40.
Bloom BM, Goldman IM. The nature of catecholamine-adenine mononucleotide interactions in adrenergic mechanisms. In: Harper NJ, Simmonds AB, eds. Advances in Drug Research. Vol. 3. London: Academic Press 1966:121–69.
Robison GA, Butcher RW, Sutherland EW. Adenylcyclase as an adrenergic receptor. Ann NY Acad Sci 1967;139:703–23.
Birnbaumer L, Pohl SL, Krans HMJ, Rodbell M. Actions of hormones on the adenyl cyclase system. Adv Biochem Psychopharmacol 1970;3:185–208.
Rodbell M, Birnbaumer L, Pohl SL, Krans HMJ. The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. v. An obligatory role of guanylnucleotides in glucagon action. J Biol Chem 1971;246:1877–82.
Cuatrecasas P. Membrane receptors. Ann Rev Biochem 1974;43:169–214.
Singer SJ, Nicholson GL. The fluid mosaic model of the structure of cell membranes. Science 1972;175:720–31.
Singer SJ. The fluid mosaic model of membrane structure: some applications to ligand-receptor and cell-cell interactions. In: Bradshaw RA, Frazier WA, Merrell RC, et al., eds. Surface membrane receptors. New York: Plenum Press, 1976:1–24.
Cuatrecasas P. Hormone receptors — their function in cell membranes and some problems related to methodology. Adv Cyclic Nucleotide Res 1975;5:79–104.
Jacobs S, Cuatrecasas P. The mobile receptor hypothesis and ‘cooperativity’ of hormone binding. Application to insulin. Biochim Biophys Acta 1976;433:482–95.
Ariëns EJ, Beld AJ, Rodrigues de Miranda JF, Simonis AM. The pharmacon-receptor-effector concept. A basis for understanding the transmission of information in biological systems. In: O'Brien RD, ed. The Receptors. Vol. 1. New York: Plenum Press, 1979:33–91.
Changeux JP, Thiery J, Tung Y, Kittel C. The cooperativity of biological membranes. Proc Natl Acad Sci USA 1967;57:335–41.
Karlin A. The application of ‘a plausible model’ of allosteric proteins to the receptor for acetylcholine. J Theor Biol 1967;16:306–20.
Thron CD. Analysis of pharmacological experiments in terms of an allosteric receptor model. Mol Pharmacol 1973;9:1–9.
Lefkowitz RJ, Haber E. Fraction of the ventricular myocardium that has the specificity of the cardiac beta-adrenergic receptor. Proc Natl Acad Sci USA 1971;68:1773–7.
Cuatrecasas P, Tell GPE, Sica V, Parikh I, Chang KJ. Noradrenaline binding and the search for catecholamine receptors. Nature (Lond) 1974;247:92–7.
Aurbach GD, Fedak SA, Woodward CJ, Palmer JS, Hauser D, Troxler F. Beta-adrenergic receptor: stereospecific interaction of iodinated beta-blocking agent with high affinity site. Science 1974;186:1223–4.
Lefkowitz RJ, Mukherjec C, Coverstone M, Caron MG. Stereospecific [3H](-)alprenolol binding sites, beta-adrenergic receptors and adenylate cyclase. Biochem Biophys Res Commun 1974;60:703–9.
Engel G, Hoyer D, Berthold R, Wagner H. (+,−)-[125Iodo]cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. Naunyn-Schmiedebergs Arch Pharmacol 1981;317:277–85.
Barovsky K, Brooker G. (−) [125I]-iodopindolol, a new highly selective radioiodinated beta-adrenergic receptor antagonist: measurement of beta-receptors on intact rat astrocytoma cells. J Cyclic Nucleotide Res 1980;6:297–307.
Staehelin M, Simons P. Rapid and reversible disappearance of beta-adrenergic cell surface receptors. EMBO J 1982;1:187–90.
Ross EM, Gilman AG. Biochemical properties of hormone-sensitive adenylate cyclase. Ann Rev Biochem 1980;49:533–64.
Lefkowitz RJ, Caron MG, Michel T, Stadel JM. Mechanisms of hormone receptor-effector coupling: the beta-adrenergic receptor and adenylate cyclase. Fed Proc 1982;41:2664–70.
Vauquelin G, Geynet P, Hanoune J, Strosberg AD. Isolation of adenylate cyclase-free, beta-adrenergic receptor from turkey erythrocyte membranes by affinity chromatography. Proc Natl Acad Sci USA 1977;74:3710–4.
Caron MG, Srinivasan Y, Pitha J, Kociolek K, Lefkowitz RJ. Affinity. chromatography of the beta-adrenergic receptor. J Biol Chem 1979;254:2923–7.
Stiles GL, Strasser RH, Lavin TN, Jones LR, Caron MG, Lefkowitz RJ. The cardiac beta-adrenergic receptor. J Biol Chem 1983;258:8443–9.
Shorr RGL, Lefkowitz RJ, Caron MG. Purification of the beta-adrenergic receptor. Identification of the hormone binding subunit. J Biol Chem 1981;256:5820–6.
Shorr RGL, Strohsacker MW, Lavin TN, Lefkowitz RJ, Caron MG. The beta1-adrenergic receptor of the turkey erythrocyte: molecular heterogeneity revealed by purification and photo-affinity labelling. J Biol Chem 1982;257:12341–50.
Sibley DR, Peters JR, Nambi P, Caron MG, Lefkowitz RJ. Photo-affinity labelling of turkey erythrocyte betaadrenergic receptors: degradation of the M1 = 49,000 protein explains apparent heterogeneity. Biochem Biophys Res Commun 1984;119:458–64.
Shorr RGL, Heald SL, Jeffs PW, et al. The betaadrenergic receptor: rapid purification and covalent labelling by photo-affinity crosslinking. Proc Natl Acad Sci USA 1982;79:2778–82.
Cerione RA, Codina J, Benovic JL, Lefkowitz RJ, Birnbaumer L, Caron MG. The mammalian beta2adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry 1984;23:4519–25.
Stiles GL, Benovic JL, Caron MG, Lefkowitz RJ. Mammalian beta-adrenergic receptors. J Biol Chem 1984;259:8655–63.
Cushny AR. The action of optical isomers. III. Adrenalin. J Physiol (Lond) 1908;37:130–8.
Cushny AR. Biological relations of optically isomeric substances. Baltimore: Williams & Wilkins Co., 1926.
Von Euler US. Identification of sympathomimetic ergone in adrenergic nerves of cattle (Sympathin N) with laevo-noradrenaline. Acta Physiol [Scand] 1948;16:63–74.
Easson LH, Stedman E. Studies on the relationship between chemical constitution and physiological action, v. Molecular dissymmetry and physiological activity. Biochem J 1933;27:1257–66.
Ariëns EJ. Molecular Pharmacology. New York: Academic Press, 1964:244.
Blinks JR. Influence of beta-hydroxyl group on the inotropic and chronotropic activities of catecholamines. Pharmacologist 1904;6:176.
Morris TH, Kaumann AJ. Different steric characteristics of beta1- and beta2-adrenoceptors. Naunyn-Schmiedebergs Arch Pharmacol 1984;327:176–9.
Asano T, Katada T, Gilman AG, Ross EM. Activation of the inhibitory GTP-binding protein of adenylate cyclase, Gi, by beta-adrenergic receptors in reconstituted phospholipid vesicles. J Biol Chem 1984;259:9351–4.
Pfeuffer T. GTP-binding proteins in membranes and the control of adenylate cyclase activity. J Biol Chem 1977;252:7224–34.
Ross EM, Howlett AC, Ferguson KM, Gilman AG. Reconstitution of hormone-sensitive adenylate cyclase activity with resolved components of the enzyme. J Biol Chem 1978;253:6401–12.
Rodbell M. The role of hormone receptors and GTP-regulatory proteins in membrane transduction. Nature (Lond) 1980;284:17–22.
Northrup JK, Sternweis PC, Smigel MD, Schleifer LS, Ross EM, Gilman AG. Purification of the regulatory component of adenylate cyclase. Proc Natl Acad Sci USA 1980;77:6516–20.
Hanski E, Sternweis PC, Northrup JK, Dromerick AW, Gilman AG. The regulatory component of adenylate cyclase. Purification and properties of the turkey erythrocyte protein. J Biol Chem 1981;256:12911–9.
Hanski E, Gilman AG. The guanine nucleotidebinding regulatory component of adenylate cyclase in human erythrocytes. J Cyclic Nucleotide Res 1982;8:323–36.
Northrup JK, Sternweis PC, Gilman AG. The subunits of the stimulatory regulatory component of adenylate cyclase. Resolution, activity and properties of the 35,000-dalton (beta) subunit. J Biol Chem 1983; 258:11361–8.
Northrup JK, Smigel MD, Sternweis PC, Gilman AG. The subunits of the stimulatory regulatory component of adenylate cyclase. Resolution of the activated 45,000-dalton (alpha) subunit. J Biol Chem 1983; 258:11369–76.
Hildebrandt JD, Codina J, Risinger R, Birnbaumer L. Identification of a gamma subunit associated with the adenylyl cyclase regulatory proteins Ns and Nj. J Biol Chem 1984;259:2039–42.
Bokoch GM, Katada T, Northrup JK, Hewlett EL, Gilman AG. Identification of the predominant substrate for ADP-ribosylation by islet activating proteins. J Biol Chem 1983;258:2072–5.
Manning DR, Gilman AG. The regulatory components of adenylate cyclase and transducin. A family of structurally homologous guanine nucleotide-binding proteins. J Biol Chem 1983;258:7059–63.
Katada T, Bokoch GM, Northrup JK, Ui M, Gilman AG. The inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. Properties and function of the purified protein. J Biol Chem 1984;259:3568–77.
Katada T, Northup JK, Bokoch GM, Ui M, Gilman AG. The inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. Subunit dissociation and guanine nucleotide-dependent hormonal inhibition. J Biol Chem 1984;259:3578–85.
Jacobs KH, Schultz G. Occurrence of a hormonesensitive inhibitory coupling component of the adenylate cyclase in S49 lymphoma cyc variants. Proc Natl Acad Sci USA 1983;80:3899–902.
Katada T, Bokoch GM, Smigel MD, Ui M, Gilman AG. The inhibitory guanine-nucleotide binding regulatory component of adenylate cyclase. Subunit dissociation and the inhibition of adenylate cyclase in S49 lymphoma cyc and wild type membranes. J Biol Chem 1984;259:3586–95.
Stryer L, Hurley JB, Fung BKK. First stage of amplification in the cyclic-nucleotide cascade of vision. Curr Top Membrane Trans 1981;15:93–108.
Fung BKK. Characterization of transducin from bovine retinal rod outer segments. I. Separation and reconstitution of the subunits. J Biol Chem 1983;258:10495–502.
Ross EM. Physical separation of the catalytic unit and regulatory proteins of hepatic adenylate cyclase. J Biol Chem 1981;256:1949–53.
Drummond GI. Properties of the resolved catalytic unit of skeletal muscle adenylate cyclase. Arch Biochem Biophys 1984;235:427–37.
Pfeuffer T, Metzger H. 7-O-Hemisuccinyl-deacetyl forskolin-Sepharose: a novel affinity support for purification of adenylate cyclase. FEBS Lett 1982;146:369–75.
Pfeuffer T, Gaugler B, Metzger H. Isolation of homologous and heterologous complexes between catalytic and regulatory components of adenylate cyclase by forskolin-sepharose. FEBS Lett 1983;164:154–60.
Pfeuffer E, Dreher RM, Metzger H, Pfeuffer T. Catalytic unit of adenylate cyclase: purification and identification by affinity crosslinking. Proc Natl Acad Sci USA 1985;82:3086–90.
Seamon KB, Daly JW. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 1981; 256:9799–801.
Insel PA, Stengel D, Ferry N, Hanoune J. Regulation of adenylate cyclase of human platelet membranes by forskolin. J Biol Chem 1982;257:7485–90.
Houslay MD, Ellory JC, Smith Hesketh TR, Stein JM, Warren GD, Metcalfe JC. Exchange in partners in glucagon receptor-adenylate cyclase complexes. Physical evidence for the independent mobile receptor model. Biochem Biophys Acta 1977;467:208–19.
Andreasen TJ, Heideman W, Rosenberg GB, Storm DR. Photo-affinity labeling of brain adenylate cyclase preparations with azido [125I]iodocalmodulin. Biochemistry 1983;22:2757–62.
Levitzki A. Activation and inhibition of adenylate cyclase by hormones: mechanistic aspects. TIPS 1982;3:203–7.
Arad H, Rosenbüsch JP, Levitzki A. Stimulatory GTP regulatory unit Ns and the catalytic unit of adenylate cyclase are tightly associated: mechanistic consequences. Proc Natl Acad Sci USA 1984;81:6579–83.
Lefkowitz RJ, DeLean A, Hofmann BB, et al. Molecular pharmacology of adenylate cyclase-coupled alpha- and beta-adrenergic receptors. Adv Cyclic Nucleotide Res 1981;14:145–61.
Gilman AG. Guanine nucleotide-binding regulatory proteins and dual control of adenylate cyclase. J Clin Invest 1984;73:1–4.
Sternweis PC, Gilman AG. Aluminium: a requirement for activation of the regulatory component of adenylate cyclase by fluoride. Proc Natl Acad Sci USA 1982;79:4888–91.
Ross EM. Phosphatidylcholine-promoted interaction of the catalytic and regulatory proteins of adenylate cyclase. J Biol Chem 1982:257-10751-8.
Cech SY, Broaddus WC, Maguire ME. Adenylate cyclase: the role of magnesium and other divalent cations. Mol Cell Biochem 1980;33:67–92.
Garbers DL, Johnson RA. Metal and metal-ATP interactions with brain and cardiac adenylate cyclases. J Biol Chem 1975;250:8449–56.
Cech SY, Maguire ME. Magnesium regulation of the beta-receptor-adenylate cyclase complex. I. Effects of manganese on receptor binding and cyclase activation. Mol Pharmacol 1982;22:267–73.
Maguire ME. Magnesium regulation of the betareceptor-adenylate cyclase complex. II. Scandium as a magnesium antagonist. Mol Pharmacol 1982;22:274–80.
Cassel D, Sellinger Z. Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc Natl Acad Sci USA 1977;74:3307–11.
Johnson GL, Kaslow HR, Farfel Z, Bourne HR. Genetic analysis of hormone sensitive adenylate cyclase. Adv Cyclic Nucleotide Res 1980;13:2–38.
Kent RS, DeLean A, Lefkowitz RJ. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modelling of ligand binding data. Mol Pharmacol 1980;17:14–23.
DeLean A, Hancock AA, Lefkowitz RJ. Validation and statistical analysis of a computer modelling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol 1982;21:5–16.
DeLean A, Stadel J, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 1980;255:7108–17.
Limbird E, Gill DM, Lefkowitz RJ. Agonist promoted coupling of the beta-adrenergic receptors with the guanine nucleotide regulatory protein of the adenylate cyclase. Proc Natl Acad Sci USA 1980;77:775–9.
Limbird E, Lefkowitz RJ. Agonist induced increase in apparent beta-adrenergic receptor size. Proc Natl Acad Sci USA 1978;75:228–32.
Weiland GA, Minneman KP, Molinoff PB. Fundamental difference between the molecular interactions of agonists and antagonists with the beta-adrenergic receptor. Nature (Lond) 1979;281:114–7.
Weiland GA, Minneman KP, Molinoff PB. Thermodynamics of agonist and antagonist interactions with mammalian beta-adrenergic receptors. Mol Pharmacol 1980;18:341–7.
Vauquelin G, Maguire ME. Inactivation of betaadrenergic receptors byN-ethylmaleimide in S49 lymphoma cells. Mol Pharmacol 1980;18:362–9.
Jacobsson B, Vauquelin G, Wesslau C, Smith U, Strosberg AD. Distinction between two subpopulations of beta1-adrenergic receptors in human adipose cells. Eur J Biochem 1981;114:349–54.
Korner M, Gilon C, Schramm M. Locking of hormone in the beta-adrenergic receptor by attack on a sulfhydryl in an associated component. J Biol Chem 1982;257:3389–96.
Tolkovsky AM. The elucidation of some aspects of receptor function by the use of a kinetic approach. Curr Top Membrane Trans 1983;18:11–44.
Cerione RA, Strulovici B, Benovic JL, Lefkowitz RJ, Caron MG. The pure beta-adrenergic receptor: a single polypeptide confers catecholamine responsiveness to an adenylate cyclase system. Nature (Lond) 1983; 306:562–6.
Cerione RA, Staniszewski C, Benovic JL, et al. Specificity of the functional interactions of the betaadrenergic receptor and rhodopsin with guanine nucleotide regulatory proteins reconstituted in phospholipid vesicles. J Biol Chem 1985;260:1493–500.
Asano T, Ross EM. Catecholamine-stimulated guanosine 5′-O-(3-thiotriphosphate) binding to the stimulatory GTP-binding protein of adenylate cyclase: kinetic analysis in reconstituted phospholipid vesicles. Biochemistry 1984;23:5467–71.
Asano T, Pedersen SE, Scott CW, Ross EM. Reconstitution of catecholamine-stimulated binding of guanosine 5′-O-(3-thiotriphosphate) to the stimulatory GTP-binding protein of adenylate cyclase. Biochemistry 1984;23:5460–7.
Cerione RA, Staniszewski C, Caron MG, Lefkowitz RJ, Codina J, Birnbaumer L. A role for Ni in the hormonal stimulation of adenylate cyclase. Nature (Lond) 1985;318:293–5.
Codina J, Hildebrandt JD, Sekura RD et al. Ns and Ni, the stimulatory and inhibitory regulatory components of adenylyl cyclases: purification of the human erythrocyte proteins without the use of activating regulatory ligands. J Biol Chem 1984;259:5871–86.
Cassel D, Selinger Z. Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes. Biochim Biophys Acta 1976;452:538–51.
Pike LJ, Lefkowitz RJ. Activation and desensitization of beta-adrenergic receptor-coupled GTPase and adenylate cyclase of frog and turkey erythrocyte membranes. J Biol Chem 1980;255:6860–7.
Brandt DR, Asano T, Pedersen SE, Ross EM. Reconstitution of catecholamine stimulated guanosine triphosphatase activity. Biochemistry 1983;22:4357–62.
Hirata F, Strittmatter J, Axelrod J. Beta-adrenergic receptor agonists increase phospholipid methylation, membrane fluidity, and beta-adrenergic receptor-adenylate cyclase coupling. Proc Natl Acad Sci USA 1979;76:368–72.
Harden TK. Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase. Pharmacol Rev 1983;35:5–32.
Sibley DR, Lefkowitz RJ. Molecular mechanisms of receptor desensitization using the beta-adrenergic receptor-coupled adenylate cyclase system as a model. Nature (Lond) 1985;317:124–9.
Dixon RAF, Kobilka BK, Strader DJ, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature (Lond) 1986;321:75–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ijzerman, A.P., Timmerman, H. The beta-adrenoceptor-adenylate cyclase complex. Pharmaceutisch Weekblad Scientific Edition 8, 209–222 (1986). https://doi.org/10.1007/BF01957781
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01957781